BioMarin Pharmaceutical Inc. · BMRN · FY2026 Q2 · Calendar Q3 2026
BioMarin raises 2026 outlook as Amicus products lift Q2 growth
BioMarin’s Q2 update supports a growth case built on Amicus product contribution, established rare-disease products and geographic and diagnostic expansion. Whether that growth translates into durable earnings depends in part on integration synergies, financing costs, patient retention and regulatory outcomes.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about BMRN FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management said Q2 revenue grew 20% year over year to nearly $1 billion and raised full-year 2026 revenue and non-GAAP EPS guidance. The call also put a figure on expected annual Amicus cost synergies—$220 million, with full realization expected by 2028—and described rapid submission of the Voxzogo hypochondroplasia application.
Guidance delta
Raised full-year 2026 revenue and non-GAAP EPS guidance; the supplied current-quarter analysis does not provide the revised ranges.
Key takeaways
- Q2 revenue grew 20% year over year to nearly $1 billion, with double-digit Voxzogo growth and strong Galafold and Pombility/Opfolda launches.
- Management raised full-year 2026 revenue and non-GAAP EPS guidance.
- Management identified $220 million in annual Amicus cost synergies, expected to be fully realized by 2028.
- The Voxzogo hypochondroplasia supplemental NDA was submitted; management also highlighted late-stage BMN 28 development for FSGS.
Management priorities
- Expand diagnosis initiatives, including newborn and cascade screening, to grow the number of U.S. patients treated with Galafold.
- Expand Galafold, Pombility and Opfolda into additional international markets.
- Advance Voxzogo label expansion and the BMN 28 program while integrating the Amicus portfolio and realizing planned synergies.
Follow BMRN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels.…
Historical context
All BMRN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
- SBACFY2026 Q3 · November 2, 2026+4.8% EPS-1.2% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the BMRN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-02T22:04:52.236366+00:00
- FN2 earnings calendar · 2026-09-11T01:23:15.000588+00:00
- Polygon adjusted daily market bars · 2026-11-03T08:20:45.523112+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T08:20:45.520280+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.